The interleukin-18 -607A/C polymorphism is not associated with risk for oral cancer

Anticancer Research

Volumn 27, Issue 6 B, 2007, Pages 4011-4014

  Vairaktaris, Eleftherios ^a   Serefoglou, Zoe Charalambus ^a   Yapijakis, Christos ^a   Agapi, Chatzitheofylaktou ^a   Vassiliou, Stavros ^a   Nkenke, Emeka ^b   Antonis, Vylliotis ^a   Sofia, Spyridonidou ^a   Neukam, Friedrich Wilhelm ^b   Patsouris, Efstratios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Angiogenesis; DNA polymorphism; Inflammation; Interleukin 18; Oncogenesis; Oral cancer; Thrombophilia

Indexed keywords

INTERLEUKIN 18;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; DRINKING BEHAVIOR; GENE FREQUENCY; GENETIC TRANSCRIPTION; HUMAN; MAJOR CLINICAL STUDY; MOUTH CANCER; PRIORITY JOURNAL; PROMOTER REGION; SMOKING HABIT; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; INTERLEUKIN-18; MALE; MIDDLE AGED; MOUTH NEOPLASMS; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); TRANSCRIPTION, GENETIC;

EID: 37549044200     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. McDowell JD: An overview of epidemiology and common risk factors for oral squamous cell carcinoma. Otolaryngol Clin North Am 39: 277-294, 2006.
2. Schimming R, Reusch P, Kuschnierz J and Schmelzeisen: Angiogenic factors in squamous cell carcinoma of the oral cavity: do they have prognostic relevance? J Craniomaxillofac Surg 32: 176-181, 2004.
3. Johnstone S and Logan RM: The role of vascular endothelial growth factor (VEGF) in oral dysplasia and oral squamous cell carcinoma. Oral Oncol 42: 337-342, 2006.
4. Vairaktaris E, Yapijakis C, Kessler P, Vylliotis A Ries J, Wiltfang J, Vassiliou S, Derka S and Neukam FW: Methylenetetrahydrofolate reductase polymorphism and minor increase of risk for oral cancer. J Cancer Res Clin Oncol 132: 219-222, 2006.
5. Vairaktaris E, Yapijakis C, Serefoglou Z, Vylliotis A, Ries J, Nkenke E, Wiltfang J, Derka S, Vassiliou S, Springer I, Kessler P and Neukam FW: Plasminogen activator inhibitor-1 polymorphism is associated with increased risk for oral cancer. Oral Oncol 42: 888-892, 2006.
6. Vairaktaris E, Yiannopoulos A, Vylliotis A, Yapijakis C, Derka S, Vassiliou S, Nkenke E, Serefoglou Z, Ragos V, Papageorgiou G, Vorris E, Critseli E, Avgoustidis D, Neukam F and Patsouris E: Strong association of interleukin-6 -174G>C promoter polymorphism with increased risk of oral cancer. Int J Biol Markers 21: 246-250, 2006.
7. Vairaktaris E, Yapijakis C, Serefoglou Z, Derka S, Vassiliou S, Nkenke E, Vylliotis A, Wiltfang J, Avgoustidis D, Critselis E and Neukman FW: The interleukin-8 (-251A/T) polymorphism is associated with increased risk for oral squamous cell carcinoma. Eur J Surg Oncol 33(4): 504-507, 2007.
8. Vairaktaris E, Yapijakis C, Derka S, Serefoglou Z, Vassiliou S, Nkenke E, Ragos V, Vylliotis A, Spyridonidou S, Tsigris C, Yannopoulos A Tesseromatis C, Neukam FW and Patsouris E: Association of matrix metalloproteinase-1 (-1607 1G/2G) polymorphism with increased risk for oral squamous cell carcinoma. Anticancer Res 27(1A): 459-464, 2007.
9. Vairaktaris E, Serefoglou Z, Yapijakis C, Vylliotis A, Nkenke E, Derka S, Vassiliou S, Avgoustidis D, Neukam FW and Patsouris E: High gene expression of matrix metalloproteinase-7 is associated with early stages of oral cancer. Anticancer Res 27(4B): 2493-2498, 2007.
10. Vairaktaris E, Serefoglou Z, Yapijakis C, Nkenke E, Vassiliou S, Spyridonidou S, Vylliotis A, Nixon AM, Neukam FW and Patsouris E: Coagulation-related factors thrombomodulin and protein Z are associated with risk for oral cancer. Anticancer Res 27(4B): 2449-2452, 2007.
11. Mallat Z, Henry P, Fressonnet R, Alouani S, Scoazec A, Beaufils P, Chvatchko Y and Tedgui A: Increased plasma concentrations of interleukin-18 in acute coronary syndromes. Heart 88(5): 467-469, 2002.
12. Dinarello CA: Interleukin-18 and the pathogenesis of inflammatory diseases. Semin Nephrol 27(1): 98-114, 2007.
13. Nilkaeo A and Bhuvanath S: Role of interleukin-18 in modulation of oral carcinoma cell proliferation. Mediat Inflamm 2006(3): 1-6, 2006.
14. Dinarello CA: Interleukin-18, a proinflammatory cytokine. Euro Cytok Netw 11(3): 483-486, 2000.
15. Akira S: The role of IL-18 in innate immunity. Curr Opin Immunol 12(1): 59-63, 2000.
16. Yoshimoto T, Takeda K, Tanaka T, Ohkusu K, Kashiwamura S, Okamura H, Akira S and Nakanishi K: IL-12 up-regulates IL-18 receptor expression on T-cells, Th1 cells, and B cells: Synergism with IL-18 for IFN-γ production. J Immunol 161: 3400-3407, 1998.
17. Cai G, Kastelein RA and Hunter CA: IL-10 enhances NK cell proliferation, cytotoxicity and production of IFN-γ when combined with IL-18. Eur J Immunol 29: 2658-2665, 1999.
18. Golab J: Interleukin-18-interferon γ inducing factor-α novel player in tumor immunotherapy? Cytokine 12(4): 332-338, 2000.
19. Pages F, Berger A, Henglein B, Piqueras B, Danel C, Zinzindohoue F, Thiounn N, Cugnenc PH and Fridman WH: Modulation of interleukin-18 expression in human colon carcinoma: Consequences for tumor immune surveillance. Int J Cancer 84: 326-330, 1999.
20. Nicolini A, Carpi A and Rossi G: Cytokines in breast cancer. Cytokine Growth Factor Rev 17: 325-337, 2006.
21. Wang ZY, Gaggero A, Rubartelli A, Rosso O, Miotti S, Mizzanzanica D, Canevari S and Ferrini S: Expression of interleukin-18 in human ovarian carcinoma and normal ovarian epithelium: Evidence for defective processing in tumor cells. In J Cancer 98: 873-878, 2002.
22. Park H, Byun D, Kim TS, Kim YI, Kang JS, Hahm ES, Kim SH, Lee WJ, Song HK, Yoon DY, Kang CJ, Lee C, Houh D, Kim H, Cho B, Kim Y, Yang YH, Min KH and Cho DH: Enhanced IL-18 expression in common skin tumors. Immunol Lett 79: 215-219, 2001.
23. Lebel-Binay S, Thiounn N, De Pinieux G, Viellefond A, Debré B, Bonnefoy JY, Fridman WH, and Pages F: IL-18 is produced by prostate cancer cells and secreted in response to interferons. Int J Cancer 106: 827-835, 2003.
24. Wen Z, Ouyang Q, Chen D and Su X: Interleukin 18 expression in colon cancer and adenoma. Sichuan Da Xue Xue Bao Yi Xue Ban 34(2): 262-264, 2003 (article in Chinese).
25. Riedel F, Adam S, Feick P, Haas S Gotte K and Hörmann K: Expression of IL-18 in patients with head and neck squamous cell carcinoma. Int J Mol Med 13(2): 267-272, 2004.
26. Alexandrakis MG, Passam FH, Sfiridaki K, Moschandrea J, Pappa C, Liapi D, Petreli E, Roussou P and Kyriakou DS: Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival. Leukemia Res 28: 259-266, 2004.
27. Zhang B, Wu KF, Cao ZY, Rao Q, Ma XT, Zheng GG and Li G: IL-18 increases invasiveness of HL-60 myeloid leukemia cells: up-regulation of matrix metalloproteinase-9 (MMP-9) expression. Leukemia Res 28: 91-95, 2004.
28. Diakowska D, Markocka-Maczka K, Grabowski K and Lewandowski A: Serum interleukin-12 and interleukin-18 levels in patients with esophageal squamous cell carcinoma. Exp Oncol 28(4): 319-322, 2006.
29. Asakawa M, Kono H, Amemiya H, Matsuda M, Suzuki T, Maki A and Fujii H: Role of interleukin-18 and its receptor in hepatocellular carcinoma associated with hepatitis C virus infection. Int J Cancer 118: 564-570, 2006.
30. Ye ZB, Ma T, Li H, Jin XL and Xu HM: Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma. World J Gastroenterol 13(11): 1747-1751, 2007.
31. Lissoni P, Brivio F, Rovelli F, Fumagalli G, Malugani F, Vaghi M, Secondino S, Bucovec R and Gardani GS: Serum concentrations of interleukin-18 in early and advanced cancer patients: enhanced secretion in metastatic disease. J Boil Regul Homoest Agents 14(4): 275-277, 2000.
32. Cao R, Farnebo J, Kurimoto M and Cao Y: Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB 13: 2195-2202, 1999.
33. Giedraitis V, He B, Huang WX and Hillert J: Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. J Neuroimmunol 112: 146-152, 2001.
34. Kruse S, Kuehr J, Moseler M, Kopp MV, Kurz T, Deichmann KA, Foster PS, and Mattes J: Polymorphisms in the IL18 gene are associated with specific sensitization to common allergens and allergic rhinitis. J Allergy Clin Immunol 111(1): 117-122, 2003.
35. Kretowski A, Mironczuk K, Karpinska A, Bojaryn U, Kinalski M, Puchalski Z and Kinalska I: Interleukin-18 promoter polymorphisms in type 1 diabetes. Diabetes 51: 3347-3349, 2002.
36. Rueda B, González-Gay MA, Mataran L, López-Nevot and Martín J: Interleukin-18 promoter polymorphisms are not prevalent in rheumatoid arthritis. Tissue antigens 65: 544-548, 2005.
37. Zhang PA, Wu JM, Li Y and Yang XS: Relationship of interleukin-18 gene promoter polymorphisms with chronic hepatitis B in the Chinese Han population. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 22(5): 528-532, 2005 (in Chinese).
38. Lee HM, Park SA, Chung SW, Woo JS, Chae SW, Lee SH, Kang HJ and Hwang SJ: Interleukin-18/-607 gene polymorphism in allergic rhinitis. Int J Pediatr Otorhinolaryngol 70: 1085-1088, 2006.
39. Dong GP, Yu ZS, Liang L, Zou CC, Fu ZJ and Wang CL: IL-18 gene promoter -137C/G and -607C/A polymorphisms in Chinese Han children with type 1 diabetes mellitus. Int J Immunogenet 34: 75-79, 2007.
40. Moore MB, Kurago ZB, Fullenkamp CA and Lutz CT: Squamous cell carcinoma cells differentially stimulate NK cell effector functions: the roleof IL-18. Cancer Immunol Immunother 52: 107-115, 2003.
41. Jablonska E, Puzewska W, Grabowska Z, Jablonski J and Talarek L: VEGF, IL-18 and NO production by neutrophils and their serum levels in patients with oral cavity caner. Cytokine 30: 93-99, 2005.
42. Pratesi C, Bortolin MT, Bidoli E, Tedeschi R, Vaccher E, Dolcetti R, Guidoboni M, Franchin G, Barzan L, Zanussi S, Caruso C and De Paoli P: Interleukin-10 and interleukin-18 promoter polymorphisms in an Italian cohort of patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Immunol Immunother 55: 23-30, 2006.